BioSpace News Archive

Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system (“CNS”), today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer.

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) is pleased to announce that it has successfully submitted an Investigational New Drug (‘IND’) application to the US Food and Drug Administration (‘FDA’) for IHL-42X for treatment of obstructive sleep apnoea.

PTC Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion for the extension of the Evrysdi® marketing authorization to include infants under two months of age in the European Union.

Pharvaris (Nasdaq: PHVS) today shared data from the RAPIDe-1 Phase 2 clinical study of PHVS416 (deucrictibant immediate-release capsules) for the on-demand treatment of HAE attacks, including data focused on time-to-symptom relief and resolution of HAE attacks, in two poster presentations at the 2023 U.S. HAEA National Summit, taking place in Orlando, Florida from July 20-23.

GC Biopharma, a South Korean biopharmaceutical company, announced on the 18th that its quadrivalent flu vaccine called GC FLU Quadrivalent Pre-filled syringe inj.

AbbVie announced the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of conditional marketing authorization for epcoritamab as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.

Enzolytics, Inc. announced today a partnership with Khalpey AI Lab to identify biomarkers for early onset Alzheimer’s disease.

RedHill Biopharma Ltd. today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 1,301,923 of the Company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS representing four hundred (400) ordinary shares, at a purchase price of $1.35 per ADS (or ADS equivalent), in a registered direct offering.

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 7MW3711 for advanced malignant solid tumor was approved by the National Medical Products Administration (NMPA).

Ilumed announced today that Marco Castillo has been appointed the new Chief Transformation Officer of the company, tasked with leading continued growth for the company’s operations in ten states.